NASDAQ:ICLR

ICON Public (ICLR) Stock Forecast, Price & News

$213.03

+4.56 (+2.19%)

(As of 05/31/2023 ET)

Compare

Today's Range: $206.41
▼
$213.41
50-Day Range: $183.12
▼
$215.91
52-Week Range: $171.43
▼
$249.62

Volume: 634,370 shs
Average Volume: 712,286 shs
Market Capitalization: $17.45 billion

P/E Ratio: 34.47
Dividend Yield: N/A
Price Target: $257.30

ICON Public MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 20.8% Upside
$257.30 Price Target
Short Interest: Healthy
1.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.24
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 15.66%
From $11.88 to $13.74 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

101st out of 1,006 stocks

Commercial Physical Research Industry

5th out of 16 stocks

2.5

Analyst's Opinion

Consensus Rating
ICON Public has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $257.30, ICON Public has a forecasted upside of 20.8% from its current price of $213.03.
Amount of Analyst Coverage
ICON Public has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.45% of the float of ICON Public has been sold short.
Short Interest Ratio / Days to Cover
ICON Public has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
ICON Public does not currently pay a dividend.
Dividend Growth
ICON Public does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ICLR.

3.5

News and Social Media Coverage

News Sentiment
ICON Public has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for ICON Public this week, compared to 2 articles on an average week.
Search Interest
4 people have searched for ICLR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
5 people have added ICON Public to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ICON Public insiders have not sold or bought any company stock.
Percentage Held by Insiders
44.00% of the stock of ICON Public is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
92.32% of the stock of ICON Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for ICON Public are expected to grow by 15.66% in the coming year, from $11.88 to $13.74 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ICON Public is 34.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.89.
Price to Earnings Ratio vs. Sector
The P/E ratio of ICON Public is 34.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 146.37.
Price to Earnings Growth Ratio
ICON Public has a PEG Ratio of 1.20. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
ICON Public has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ICON Public (NASDAQ:ICLR) Stock

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Stock News Headlines

May 31, 2023 | finance.yahoo.com

ICON plc to Attend Upcoming Investor Conferences

May 18, 2023 | americanbankingnews.com

Analysts Set ICON Public Limited (NASDAQ:ICLR) Target Price at $257.30

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin

$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.

May 16, 2023 | finance.yahoo.com

ICON releases its 2022 ICON Cares ESG Report

May 8, 2023 | americanbankingnews.com

Financial Comparison: ICON Public (NASDAQ:ICLR) and OmniAb (NASDAQ:OABI)

May 5, 2023 | benzinga.com

Will Chart Analysts Notice Bad Omen on Icon's Chart

May 3, 2023 | americanbankingnews.com

ICON Public Limited Expected to Post Q1 2024 Earnings of $3.18 Per Share (NASDAQ:ICLR)

May 3, 2023 | americanbankingnews.com

Brokers Set Expectations for ICON Public Limited's Q3 2023 Earnings (NASDAQ:ICLR)

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin

May 2, 2023 | americanbankingnews.com

ICON Public (NASDAQ:ICLR) Price Target Lowered to $220.00 at Wells Fargo & Company

May 1, 2023 | msn.com

Baird Maintains Icon (ICLR) Outperform Recommendation

May 1, 2023 | msn.com

Wells Fargo Maintains Icon (ICLR) Equal-Weight Recommendation

May 1, 2023 | markets.businessinsider.com

Baird Maintains Outperform Rating for Icon: Here's What You Need To Know

May 1, 2023 | americanbankingnews.com

ICON Public (NASDAQ:ICLR) PT Lowered to $270.00

May 1, 2023 | americanbankingnews.com

Citigroup Cuts ICON Public (NASDAQ:ICLR) Price Target to $250.00

April 29, 2023 | americanbankingnews.com

ICON Public (NASDAQ:ICLR) Shares Down 5.9%

April 29, 2023 | americanbankingnews.com

ICON Public (NASDAQ:ICLR) Price Target Cut to $263.00 by Analysts at Guggenheim

April 28, 2023 | msn.com

Guggenheim Maintains Icon (ICLR) Buy Recommendation

April 28, 2023 | msn.com

Citigroup Maintains Icon (ICLR) Buy Recommendation

April 28, 2023 | msn.com

ICON Park launches new interactive experience aboard The Wheel

April 27, 2023 | americanbankingnews.com

ICON Public (NASDAQ:ICLR) Sees Strong Trading Volume

April 26, 2023 | finance.yahoo.com

Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates

April 26, 2023 | finance.yahoo.com

ICON Reports First Quarter 2023 Results

April 25, 2023 | americanbankingnews.com

ICON Public (ICLR) Set to Announce Earnings on Wednesday

April 21, 2023 | americanbankingnews.com

ICON Public Limited (NASDAQ:ICLR) Receives $265.70 Average Target Price from Analysts

April 20, 2023 | seekingalpha.com

ICLR ICON Public Limited Company

April 6, 2023 | americanbankingnews.com

ICON Public (NASDAQ:ICLR) PT Lowered to $250.00

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Company Calendar

Last Earnings: 11/03/2021
Today: 5/31/2023
Next Earnings (Estimated): 7/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ICLR
CUSIP: N/A
CIK: 1060955
Web: www.iconplc.com
Phone: (531) 291-2000
Fax: 353-1247-6260
Employees: 41,100
Year Founded: 1990

Price Target and Rating

Average Stock Price Forecast: $257.30
High Stock Price Forecast: $280.00
Low Stock Price Forecast: $220.00
Forecasted Upside/Downside: +20.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $6.18
Trailing P/E Ratio: 34.47
Forward P/E Ratio: 17.93
P/E Growth: 1.2
Net Income: $505.30 million
Net Margins: 6.52%
Pretax Margin: 7.33%
Return on Equity: 11.16%
Return on Assets: 5.45%

Debt

Debt-to-Equity Ratio: 0.50
Current Ratio: 1.18
Quick Ratio: 1.18

Sales & Book Value

Annual Sales: $7.74 billion
Price / Sales: 2.25
Cash Flow: $18.99 per share
Price / Cash Flow: 11.22
Book Value: $105.63 per share
Price / Book: 2.02

Miscellaneous

Outstanding Shares: 81,930,000
Free Float: 45,880,000
Market Cap: $17.45 billion
Optionable: Optionable
Beta: 1.12

Social Links

Key Executives

Stephen A. Cutler
Chief Executive Officer & Executive Director

Brendan Brennan
Chief Financial Officer

Tom O'Leary
Chief Information Officer

Gregory P. Licholai
Chief Medical & Innovation Officer

Diarmaid Cunningham
Secretary, Chief Administrative Officer & EVP

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ICLR Stock - Frequently Asked Questions

Should I buy or sell ICON Public stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICLR shares.
View ICLR analyst ratings or view top-rated stocks.
What is ICON Public's stock price forecast for 2023?: 10 brokerages have issued 12 month price targets for ICON Public's shares. Their ICLR share price forecasts range from $220.00 to $280.00. On average, they expect the company's stock price to reach $257.30 in the next twelve months. This suggests a possible upside of 20.8% from the stock's current price.
View analysts price targets for ICLR or view top-rated stocks among Wall Street analysts.
How have ICLR shares performed in 2023?: ICON Public's stock was trading at $194.25 at the beginning of the year. Since then, ICLR shares have increased by 9.7% and is now trading at $213.03.
View the best growth stocks for 2023 here.
When is ICON Public's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our ICLR earnings forecast.
How were ICON Public's earnings last quarter?: ICON Public Limited (NASDAQ:ICLR) issued its quarterly earnings results on Wednesday, November, 3rd. The medical research company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.39 by $0.16. The medical research company earned $1.87 billion during the quarter, compared to analysts' expectations of $1.84 billion. ICON Public had a net margin of 6.52% and a trailing twelve-month return on equity of 11.16%. ICON Public's revenue was up 166.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 earnings per share.
What ETFs hold ICON Public's stock?: ETFs with the largest weight of ICON Public (NASDAQ:ICLR) stock in their portfolio include Harbor Health Care ETF (MEDI), iShares MSCI Ireland ETF (EIRL), VanEck Biotech ETF (BBH), Motley Fool Global Opportunities ETF (TMFG), Janus Henderson U.S. Sustainable Equity ETF (SSPX), Invesco ESG NASDAQ Next Gen 100 ETF (QQJG), VictoryShares Nasdaq Next 50 ETF (QQQN) and BNY Mellon Sustainable International Equity ETF (BKIS).
What guidance has ICON Public issued on next quarter's earnings?: ICON Public issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $12.40-$13.05 for the period, compared to the consensus earnings per share estimate of $12.67. The company issued revenue guidance of $7.94 billion-$8.34 billion, compared to the consensus revenue estimate of $8.14 billion.
What is Steve Cutler's approval rating as ICON Public's CEO?: 147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).
What is ICON Public's stock symbol?: ICON Public trades on the NASDAQ under the ticker symbol "ICLR."
Who are ICON Public's major shareholders?: ICON Public's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include CIBC Private Wealth Group LLC (0.67%), TimesSquare Capital Management LLC (0.25%), Todd Asset Management LLC (0.17%), Globeflex Capital L P (0.06%), Kornitzer Capital Management Inc. KS (0.05%) and Silvercrest Asset Management Group LLC (0.04%).
How do I buy shares of ICON Public?: Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ICON Public's stock price today?: One share of ICLR stock can currently be purchased for approximately $213.03.
How much money does ICON Public make?: ICON Public (NASDAQ:ICLR) has a market capitalization of $17.45 billion and generates $7.74 billion in revenue each year. The medical research company earns $505.30 million in net income (profit) each year or $6.18 on an earnings per share basis.
How many employees does ICON Public have?: The company employs 41,100 workers across the globe.
Does ICON Public have any subsidiaries?: The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..
Read More
How can I contact ICON Public?: ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The official website for the company is www.iconplc.com. The medical research company can be reached via phone at (531) 291-2000 or via fax at 353-1247-6260.

This page (NASDAQ:ICLR) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ICON Public (ICLR) Stock Forecast, Price & News

ICON Public MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ICON Public (NASDAQ:ICLR) Stock

ICLR Stock News Headlines

ICLR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

ICLR Stock - Frequently Asked Questions

Overall MarketRank^™